US Stocks Movement: Moderna Soared on September 24 due to Cancer Vaccine, Merck Collaboration, and mRNA Platform

Moderna Surges on September 24: Analysis

Keywords: cancer vaccine, Merck collaboration, mRNA platform

1. On August 19, the company and Merck announced that the phase III melanoma trial of the personalized cancer vaccine intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival. Five-year data showed that the risk of recurrence or death was reduced by 49% compared to using Keytruda alone.

2. On September 21, the company stated that the above phase III data will be presented at the Presidential Symposium of the 2026 European Society for Medical Oncology conference on October 24. In addition, three abstracts on personalized neoantigen therapies have been accepted for oral presentations.

3. On September 23, company management emphasized that Moderna is not positioned merely as a COVID-19 vaccine company. Its development focus includes vaccines, oncology, and rare diseases; as of June 30, 2026, the company has 4 approved products and 26 clinical development candidates.

(Disclaimer: This content is generated by AI technology, based on public information and provided for reference only. It does not constitute investment advice.)